Αρχική World News Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and... World News Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Από Ogkologos - 11 Δεκεμβρίου, 2025 534 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... 17 Δεκεμβρίου, 2021 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... 26 Απριλίου, 2022 Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... 12 Δεκεμβρίου, 2019 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... 2 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Teen With Cancer On Dream Trip To NASA Gets Surprise Call... Improving research with registered reports The Nobel Prize in Chemistry 2020 was Awarded “for the Development...